Anti-MEK2 (phospho T394) antibody (ab30622)
- Datasheet
- Specific References (1)
- Protocols
Overview
-
Product nameAnti-MEK2 (phospho T394) antibody
See all MEK2 primary antibodies -
DescriptionRabbit polyclonal to MEK2 (phospho T394)
-
Host speciesRabbit
-
Specificityab30622 recognises endogenous levels of MEK2 only when phosphorylated at Threonine 394.
-
Tested applicationsSuitable for: WB, ELISA, IHC-P, IP, ICC/IFmore details
-
Species reactivityReacts with: Mouse, Rat, Human
-
Immunogen
Synthetic phosphopeptide derived from human MEK2 around the phosphorylation site of Threonine 394.
-
Positive control
- ovary cancer cells, breast carcinoma.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
-
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg2+ and Ca2+ -
Concentration information loading... -
PurityImmunogen affinity purified
-
Purification notesThe antibody against non phosphopeptide was removed by chromatography using non phosphopeptide corresponding to the phosphorylation site.
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
Applications
Our Abpromise guarantee covers the use of ab30622 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/500 - 1/1000. Predicted molecular weight: 44 kDa. | |
| ELISA | 1/10000. | |
| IHC-P | Use at an assay dependent concentration. | |
| IP | Use at an assay dependent concentration. | |
| ICC/IF | Use a concentration of 1 - 5 µg/ml. |
Target
-
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
-
Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
-
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsMAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway. - Information by UniProt
-
Database links
- Entrez Gene: 5605 Human
- Entrez Gene: 26396 Mouse
- Entrez Gene: 58960 Rat
- Omim: 601263 Human
- SwissProt: P36507 Human
- SwissProt: Q63932 Mouse
- SwissProt: P36506 Rat
- Unigene: 465627 Human
see all -
Alternative names
- Cardiofaciocutaneous syndrome antibody
- CFC syndrome antibody
- CFC4 antibody
see all
Images
-
Western blot - Anti-MEK2 (phospho T394) antibody (ab30622)All lanes : Anti-MEK2 (phospho T394) antibody (ab30622) at 1/500 dilution
Lane 1 : extracts from ovary cancer cells.
Lane 2 : extracts from ovary cancer cells, preincubated with synthesized non phosphopeptide
Lane 3 : extracts from ovary cancer cells, preincubated
with synthesized phosphopeptide (negative control).
Predicted band size: 44 kDa
Observed band size: 46 kDa (why is the actual band size different from the predicted?) -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-MEK2 (phospho T394) antibody (ab30622)Immunohistochemical analysis of paraffin embedded breast carcinoma tissue sections, using 1/50 MEK2 (Phospho Thr394) Antibody (ab30622). Left: untreated sample; Right: sample preincubated with synthesized phosphopeptide (negative control). -
Immunocytochemistry/ Immunofluorescence - Anti-MEK2 (phospho T394) antibody (ab30622)ICC/IF image of ab30622 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab30622, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
References
This product has been referenced in:
- Fan AC et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 15:566-71 (2009). Read more (PubMed: 19363496) »
Customer reviews and Q&As
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"